Carcinoma of Unknown Primary (CUP): Causes, Symptoms, Diagnosis and Treatment — Overview, Diagnosis & Treatment Options | MyMedicPlus

Carcinoma of unknown primary (CUP) is a metastatic cancer in which the primary site of origin cannot be identified despite a standardized clinical, imaging, and pathological diagnostic workup. It accounts for approximately 3-5% of all malignancies globally, representing approximately 30,000-40,000 US cases annually. CUP is a clinically and molecularly heterogeneous entity: approximately 20% fall into clinically defined favorable subsets with substantially better prognosis and responses to site-directed therapy (e.g., treating cervical squamous CUP as head and neck cancer, or axillary adenocarcinoma as breast cancer). The remaining 80% represent unfavorable CUP, typically managed with empirical platinum-taxane chemotherapy. The widespread adoption of next-generation sequencing (NGS) and gene expression profiling is increasingly enabling molecular subclassification and access to targeted therapies in approximately 30% of CUP patients.

CUP arises when the primary tumor is clinically undetectable despite metastatic spread. Several mechanisms are proposed: the primary may have undergone spontaneous immune-mediated regression after seeding metastases (a well-documented phenomenon in melanoma and renal cell carcinoma that likely also occurs in other cancers); the primary may be too small to detect with current CT, PET-CT, or endoscopy resolution; or the primary may have been previously resected without recognition of malignancy. Autopsy series reveal that the most common underlying primaries are lung (approximately 26%), pancreas (approximately 25%), colorectal (approximately 8%), and kidney. Some CUP genuinely lack a conventional primary organ, arising from uncommitted pluripotent cancer stem cells. Risk factors for CUP mirror those of its common underlying primaries: smoking, alcohol, and occupational carcinogens.

Symptoms entirely depend on the site(s) of metastasis and vary widely. Cervical or axillary lymphadenopathy is the most frequent presentation and, when identified, defines a potentially favorable subset. Liver metastases cause right upper quadrant pain, jaundice, elevated alkaline phosphatase, and weight loss. Peritoneal carcinomatosis causes abdominal distension, ascites, and bowel obstruction. Bone metastases cause pain, pathological fractures, and hypercalcemia. Pleural effusions cause dyspnea and pleuritic chest pain. Brain metastases cause headache, focal neurological deficits, and seizures. Constitutional symptoms — progressive fatigue, anorexia, weight loss exceeding 10% of body weight — are common across all presentations and reflect the systemic metabolic burden of metastatic disease.

Comprehensive workup: CT thorax, abdomen, and pelvis with contrast; PET-CT for complete metabolic staging and to identify potential occult primary sites. Serum tumor markers: PSA (men), CA-125, CEA, AFP, beta-hCG, CA 19-9 as appropriate. Core needle biopsy with a comprehensive IHC panel including CK7, CK20, ER, PR, PSA, CDX2, TTF-1, p40, GATA3, CD30, CD117, and synaptophysin to assign likely lineage. Next-generation sequencing (NGS) for comprehensive molecular profiling including BRAF V600E, HER2, NTRK, RET, MSI/MMR, and tumor mutational burden (TMB). Gene expression profiling (GEP) assays to assign tissue of origin. BRCA1/2 germline testing for adenocarcinoma histology. Endoscopy (upper GI and colonoscopy) in clinically appropriate presentations.

Favorable subsets receive site-specific treatment: women with peritoneal serous CUP — carboplatin plus paclitaxel with or without bevacizumab, plus cytoreductive surgery if feasible (treat as ovarian cancer); axillary adenocarcinoma in women — treat as breast cancer including ER/PR testing and HER2-targeted therapy if HER2+; squamous cell carcinoma of cervical nodes — locoregional surgery and/or chemoradiation as for head and neck squamous cell carcinoma; PSA-positive adenocarcinoma in men — androgen deprivation therapy and enzalutamide as for prostate cancer. Unfavorable CUP: empirical platinum-taxane chemotherapy (carboplatin plus paclitaxel, or docetaxel). Molecular-guided therapy for actionable alterations: BRAF V600E inhibitors (dabrafenib plus trametinib), NTRK inhibitors (larotrectinib, entrectinib), HER2-directed therapy (trastuzumab plus pertuzumab), pembrolizumab for MSI-H or TMB-high (≥10 mutations/Mb) tumors.

Prognosis in carcinoma of unknown primary (CUP) depends critically on whether the patient falls into a clinically defined favorable or unfavorable subset. Favorable subsets carry substantially better outcomes: women with peritoneal papillary serous carcinoma treated as ovarian cancer achieve median OS of 18-24 months; axillary adenocarcinoma in women treated as breast cancer achieves 5-year OS of approximately 60-70%; squamous cell carcinoma of cervical nodes treated with locoregional chemoradiation achieves 5-year OS of approximately 30-50%; PSA-positive adenocarcinoma in men treated as prostate cancer achieves prolonged survival of 3-5 years or more; single resectable metastasis achieves 5-year OS of approximately 25-40%. Unfavorable CUP — the majority — has poor prognosis: median OS with empirical platinum-taxane chemotherapy is approximately 8-12 months, with a 5-year survival rate of less than 10%. Molecular-guided therapy with targeted agents (for BRAF V600E, NTRK, HER2 alterations) or pembrolizumab for MSI-H/TMB-high tumors achieves superior outcomes in approximately 15-30% of patients with actionable alterations. Key prognostic factors are performance status (ECOG 0-1 versus 2+), clinical subset (favorable versus unfavorable), number of metastatic sites, LDH, serum albumin, and presence of actionable molecular alterations identified by NGS. Long-term survivors require continued monitoring with serial CT or PET-CT every 3-6 months for 2 years, then annually, along with reassessment for molecular testing to identify emerging targets in progressive disease.

CUP itself is not preventable, as its origin is by definition undetected. However, standard cancer screening programs enable detection of the most common underlying primaries — colorectal cancer (colonoscopy from age 45), breast cancer (annual mammography), prostate cancer (PSA-based discussion), and cervical cancer (Pap smear plus HPV co-testing) — before they reach the stage where they might present as CUP. Smoking cessation, limiting alcohol intake, maintaining healthy weight, and regular physical activity reduce the risk of the cancers (lung, pancreatic, colorectal) most commonly underlying CUP. Individuals with a strong family history of cancer should undergo genetic counseling and consider germline testing for BRCA1/2, Lynch syndrome, and other hereditary cancer syndromes to facilitate early detection.

Seek prompt medical evaluation for: a new persistent lump in the neck, armpit, or groin that does not resolve within 2-3 weeks; unexplained weight loss exceeding 5% of body weight over 3 months; new jaundice or yellowing of the skin and eyes; persistent abdominal distension or ascites; unexplained bone pain or pathological fracture; persistent fatigue with no identifiable cause; or any biopsy of a metastatic lesion that shows carcinoma or adenocarcinoma without an obvious primary source. A multidisciplinary team discussion involving oncology, radiology, and pathology is essential for the CUP workup. Patients should be referred to a specialist cancer center with access to comprehensive molecular profiling (NGS) to ensure optimal workup and access to targeted therapies.